Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
diabetes mellitus 1 endocrinologydiseases
hypogonadism 11 endocrinologydiseases
metabolic syndrome 6 endocrinologydiseases
metformin 1 endocrinologydiseasesdrugs
obesity 7 endocrinologydiseases
testosterone 105 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
metformin 10986 another study in which men (n=886) participating in the Diabetes Prevention Program were treated with metformin , T levels were associated with improvements in mood [[59]]. In another study Westley et al. [[60]] showed
testosterone 74 Title: Investigative and Clinical UrologyTestosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?Abdulmaged TraishDepartments of Biochemistry and Urology,
testosterone 329 Medicine, Boston, MA, USA.Publication date (ppub): 11/2016Publication date (epub): 11/2016AbstractAlthough testosterone therapy in men with testosterone deficiency was introduced in the early 1940s, utilization of this effective
testosterone 362 date (ppub): 11/2016Publication date (epub): 11/2016AbstractAlthough testosterone therapy in men with testosterone deficiency was introduced in the early 1940s, utilization of this effective treatment approach in hypogonadal
testosterone 576 hypogonadal men is met with considerable skepticism and resistance. Indeed, for decades, the fear that testosterone may cause prostate cancer has hampered clinical progress in this field. Nevertheless, even after considerable
testosterone 962 hypogonadism. As the fears concerning prostate cancer have subsided, a new controversy regarding use of testosterone therapy and increase in cardiovascular disease was introduced. Although the new controversy was based
testosterone 1450 controversy were fanned by the lay press and academics alike. In this review we discuss the adverse effect of testosterone deficiency and highlight the numerous proven benefits of testosterone therapy on men's health and debunk
testosterone 1520 discuss the adverse effect of testosterone deficiency and highlight the numerous proven benefits of testosterone therapy on men's health and debunk the myth that testosterone therapy increases cardiovascular risk.
testosterone 1582 highlight the numerous proven benefits of testosterone therapy on men's health and debunk the myth that testosterone therapy increases cardiovascular risk. Ultimately, we believe that there is considerable scientific
testosterone 1733 Ultimately, we believe that there is considerable scientific and clinical evidence to suggest that testosterone therapy is safe and effective with restoration of physiological levels in men with testosterone deficiency,
testosterone 1829 that testosterone therapy is safe and effective with restoration of physiological levels in men with testosterone deficiency, irrespective of its etiology.INTRODUCTIONThe last 2 decades have witnessed a revolution
testosterone 1976 etiology.INTRODUCTIONThe last 2 decades have witnessed a revolution in medical management of men with testosterone (T) deficiency (TD; also known as hypogonadism) [[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]].
testosterone 18091 in general health domains of the 36-Item Short Form Survey. This is the first study to report that testosterone deficiency and severity of ED are both independently associated with reduced QoL in men with T2D [[88][89]].
testosterone 18237 both independently associated with reduced QoL in men with T2D [[88][89]]. Furthermore, ED and low testosterone are markers of poor health which impact on an individual's self-perception of their health status [[89]].RISKS
testosterone 19592 gland [[90][95][96][97][98]]. Haider et al. [[93]] examined data from 1,023 hypogonadal men receiving testosterone therapy. A total of 11 patients were diagnosed with PCa, with incidence of 54.4 per 10,000 patient-years.
testosterone 22084 increased risk of VTE due to increased hematocrit seen in some men receiving T treatment attributed to testosterone 's ability to stimulate erythropoiesis [[38]]. As a result of these observations the FDA required pharmaceutical
testosterone 22685 prescription for T therapy was not associated with an increased risk for VTE compared to men without a testosterone prescription [[11][15]]. These findings strongly suggest that T therapy does not increase the risk of
testosterone 23654 credible evidence regarding risk of CVD with T therapy [[22][23][24][25]] and the decades long fear of testosterone promoting PCa has compounded this fear [[21]]. The lay press has also created a negative atmosphere
testosterone 26949 back and bring common sense rather that emotional outbursts to the discussion. This study [[3]] gives testosterone the chance to be the "Comeback Kid".Fig. 1Testosterone therapy in men with testosterone deficiency and
testosterone 27037 [[3]] gives testosterone the chance to be the "Comeback Kid".Fig. 1Testosterone therapy in men with testosterone deficiency and differing grade of obesity produces significant and sustained weight loss. Hypogonadal
testosterone 27356 mean age, 60.62±5.56 years) and grade III (Gr. III: n=46; mean age, 60.28±5.39 years) treated with testosterone undecanoate injections for up to 6 years. Weight expressed in kilogram. Adapted from Kenny AM, et al.
testosterone 27550 from Kenny AM, et al. J Am Geriatr Soc 2010;58:1134-43 [[74]].Fig. 2Testosterone therapy in men with testosterone deficiency and differing grade of obesity produces marked and sustained reductions in waist circumference.
testosterone 27915 mean age, 60.62±5.56 years) and grade III (Gr. III: n=46; mean age, 60.28±5.39 years) Treated with testosterone undecanoate injections for up to 6 years. Adapted from Kenny AM, et al. J Am Geriatr Soc 2010;58:1134-43
testosterone 28165 (A) and low-density lipoprotein (LDL) cholesterol levels (B) and triglyceride levels (C) in men with testosterone (T) deficiency undergoing T therapy for 5 years. Adapted from Traish AM. Am J Physiol Regul Integr Comp
testosterone 28395 2016;311:R566-73 [[5]].Fig. 4Glucose concentration (A) and hemoglobin A1c (HbA1c) levels (B) in men with testosterone (T) deficiency undergoing T therapy for 5 years. Adapted from Traish AM. Am J Physiol Regul Integr Comp
testosterone 28574 Traish AM. Am J Physiol Regul Integr Comp Physiol 2016;311:R566-73 [[5]].Table 1Established benefits of testosterone therapyBenefits of T therapyReported studiesImproved sexual desire and erectile function·Corona G,
testosterone 33201 2008;299:39-52.Oral TU6↑↓Borst SE, et al. Am J Physiol Endocrinol Metab 2014;306:E433-42.TE12↑↓TE, testosterone enanthate; TU, testosterone undecanoate.Table 3Association between low testosterone and all-cause and
testosterone 33229 SE, et al. Am J Physiol Endocrinol Metab 2014;306:E433-42.TE12↑↓TE, testosterone enanthate; TU, testosterone undecanoate.Table 3Association between low testosterone and all-cause and cardiovascular mortalityStudyStudy
testosterone 33285 2014;306:E433-42.TE12↑↓TE, testosterone enanthate; TU, testosterone undecanoate.Table 3Association between low testosterone and all-cause and cardiovascular mortalityStudyStudy authors’ conclusions1. Khaw KT, et al. Endogenous
testosterone 33403 all-cause and cardiovascular mortalityStudyStudy authors’ conclusions1. Khaw KT, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation
testosterone 33647 Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007;116:2694-701.“In men, endogenous testosterone concentrations are inversely related to mortality due to cardiovascular disease and all causes. Low
testosterone 33760 concentrations are inversely related to mortality due to cardiovascular disease and all causes. Low testosterone may be a predictive marker for those at high risk of cardiovascular disease.”2. Laughlin GA, et al.
testosterone 33885 predictive marker for those at high risk of cardiovascular disease.”2. Laughlin GA, et al. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68-75.“Testosterone insufficiency in older
testosterone 34313 concentrations and risk of death in US men. Am J Epidemiol 2010;171:583-92.“Men with low free and bioavailable testosterone levels may have a higher risk of mortality within 9 years of hormone measurement.”4. Tivesten A, et
testosterone 34442 a higher risk of mortality within 9 years of hormone measurement.”4. Tivesten A, et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 2009;94:2482-8.“Elderly men
testosterone 34572 predict mortality in elderly men. J Clin Endocrinol Metab 2009;94:2482-8.“Elderly men with low serum testosterone and estradiol have increased risk of mortality, and subjects with low values of both testosterone and
testosterone 34670 serum testosterone and estradiol have increased risk of mortality, and subjects with low values of both testosterone and estradiol have the highest risk of mortality.”5. Yeap BB, et al. In older men an optimal plasma
testosterone 34785 and estradiol have the highest risk of mortality.”5. Yeap BB, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic
testosterone 34863 men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydro testosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin
testosterone 35320 Muraleedharan V, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013;169:725-33.“Low testosterone
testosterone 35432 replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013;169:725-33.“Low testosterone levels predict an increase in all-cause mortality during long-term follow-up. Testosterone replacement
testosterone 36100 identify a small subgroup of aging men at particularly high risk of dying.”8. Hyde Z, et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J Clin
testosterone 36253 disease but not other causes: the Health in Men Study. J Clin Endocrinol Metab 2012;97:179-89.“Low testosterone predicts mortality from CVD but is not associated with death from other causes.”9. Haring R, et al.
testosterone 36378 mortality from CVD but is not associated with death from other causes.”9. Haring R, et al. Low serum testosterone is associated with increased mortality in men with stage 3 or greater nephropathy. Am J Nephrol 2011;33:209-17.“In
testosterone 36750 interventions and to improve mortality risk assessment and outcome.”10. Kyriazis J, et al. Low serum testosterone , arterial stiffness and mortality in male haemodialysis patients. Nephrol Dial Transplant 2011;26:2971-7.“We
testosterone 36886 mortality in male haemodialysis patients. Nephrol Dial Transplant 2011;26:2971-7.“We showed that testosterone deficiency in male HD patients is associated with increased CVD and all-cause mortality and that increased
testosterone 37147 mechanism explaining this association.”11. Carrero JJ, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant 2011;26:184-90.“Testosterone
testosterone 37449 associated with inflammation, cardiovascular co-morbidity and outcome.”12. Malkin CJ, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96:1821-5.“In patients with
testosterone 37580 mortality in men with coronary heart disease. Heart 2010;96:1821-5.“In patients with coronary disease testosterone deficiency is common and impacts significantly negatively on survival.”13. Corona G, et al. Low testosterone
testosterone 37691 testosterone deficiency is common and impacts significantly negatively on survival.”13. Corona G, et al. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex
testosterone 38290 and stable coronary artery disease. Int J Cardiol 2010;143:343-8.“In diabetic men with stable CAD, testosterone and DHEAS deficiencies are common and related to high CV mortality. “15. Militaru C, et al. Serum
testosterone 38403 and DHEAS deficiencies are common and related to high CV mortality. “15. Militaru C, et al. Serum testosterone and short-term mortality in men with acute myocardial infarction. Cardiol J 2010;17:249-53.“A low
testosterone 38781 disease and mortality in men: the Tromsø Study. Eur J Endocrinol 2009;161:435-42.“Men with free testosterone levels in the lowest quartile had a 24% increased risk of all-cause mortality.”17. Carrero JJ, et
testosterone 38908 lowest quartile had a 24% increased risk of all-cause mortality.”17. Carrero JJ, et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009;20:613-20.“Among men
testosterone 39038 mortality risk among male dialysis patients. J Am Soc Nephrol 2009;20:613-20.“Among men treated with HD, testosterone concentrations inversely correlate with all-cause and CVD-related mortality, as well as with markers
testosterone 39301 additional treatable risk factor for patients with chronic kidney disease.”18. Shores MM, et al. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006;166:1660-5.“Low testosterone levels were associated
testosterone 39385 et al. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006;166:1660-5.“Low testosterone levels were associated with increased mortality in male veterans. Further prospective studies are needed
testosterone 39542 mortality in male veterans. Further prospective studies are needed to examine the association between low testosterone levels and mortality.”19. Shores MM, et al. Testosterone, dihydrotestosterone, and incident cardiovascular
testosterone 39622 association between low testosterone levels and mortality.”19. Shores MM, et al. Testosterone, dihydro testosterone , and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol
testosterone 39931 associated with incident CVD and all-cause mortality.”20. Araujo AB, et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:3007-19.“Low
testosterone 40063 men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:3007-19.“Low endogenous testosterone levels are associated with increased risk of all-cause and CVD death in community-based studies of men.”21.
testosterone 40230 and CVD death in community-based studies of men.”21. Lerchbaum E, et al. Combination of low free testosterone and low vitamin D predicts mortality in older men referred for coronary angiography. Clin Endocrinol
testosterone 40528 associated with fatal events in a large cohort of men referred for coronary angiography.”DHT, dihydro testosterone ; IHD, ischemic heart disease; LOH, late onset hypogonadism; CVD, cardiovascular disease; HD, hemodialysis;
testosterone 40771 disease; MACE, major adverse cardiovascular events; DHEAS, dehydroepiandrosterone sulphate; FT, free testosterone .Table 4Events contributing to the testosterone controversy1.Pearson H. A dangerous elixir? Testosterone
testosterone 40818 events; DHEAS, dehydroepiandrosterone sulphate; FT, free testosterone.Table 4Events contributing to the testosterone controversy1.Pearson H. A dangerous elixir? Testosterone therapy jacks up vigour, sex drive and mental
testosterone 41206 reporter for news@ nature.com and is based in New York.2.Basaria S, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109-22.3.Gan EH, et al. Many men are receiving unnecessary testosterone
testosterone 41316 testosterone administration. N Engl J Med 2010;363:109-22.3.Gan EH, et al. Many men are receiving unnecessary testosterone prescriptions. BMJ 2012;345:e5469.4.Baillargeon J, et al. Trends in androgen prescribing in the United
testosterone 41515 prescribing in the United States, 2001 to 2011. JAMA Intern Med 2013;173:1465-6.5.O'connor A. Men’s use of testosterone on the rise. The New York Times. 2013 Jun 3.6.Appearance of Low T centers [Internet]. Southlake (TX):
testosterone 42073 Testosterone treatments are dangerous for me. Chicago Tribune. 2013 Sep 15.10.Vigen R, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA
testosterone 42160 Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310:1829-36.11.Baillargeon J, et al. Trends in androgen prescribing in the United
testosterone 42408 Med 2013;173:1465-6.12.Finkle WD, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014;9:e85805.13.The Editorial Board. Overselling testosterone,
testosterone 42509 testosterone therapy prescription in men. PLoS One 2014;9:e85805.13.The Editorial Board. Overselling testosterone , dangerously. New York Times. 2014 Feb 4.14.FDA evaluating risk of stroke, heart attack and death with
testosterone 42638 New York Times. 2014 Feb 4.14.FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2016 [cited 2016 Jul 15].
testosterone 43367 2015;373:689-91.17.Murphy EN, et al. Doubts about treating hypogonadism due to long-term opioid use with testosterone therapy: a teachable moment. JAMA Intern Med 2014;174:1892-3.18.Wierman ME. Risks of different testosterone
testosterone 43475 testosterone therapy: a teachable moment. JAMA Intern Med 2014;174:1892-3.18.Wierman ME. Risks of different testosterone preparations: too much, too little, just right. JAMA Intern Med 2015;175:1197-8.19.Handelsman DJ. Irrational
testosterone 43611 too little, just right. JAMA Intern Med 2015;175:1197-8.19.Handelsman DJ. Irrational exuberance in testosterone prescribing: when will the bubble burst? Med Care 2015;53:743-5.20.Perls T, et al. Disease mongering
testosterone 43755 bubble burst? Med Care 2015;53:743-5.20.Perls T, et al. Disease mongering of age-associated declines in testosterone and growth hormone levels. J Am Geriatr Soc 2015;63:809-11.21.Health Canada. Summary safety review -
testosterone 43869 and growth hormone levels. J Am Geriatr Soc 2015;63:809-11.21.Health Canada. Summary safety review - testosterone replacement products – cardiovascular risk [Internet]. Ottawa (ON): Health Canada; 2015 [cited 2016
testosterone 44063 Canada; 2015 [cited 2016 Jul 15]. Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/ testosterone -eng.php.22.Testosterone products: FDA/CDER statement of risk of venous blood clots [Internet]. Silver
testosterone 44413 http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm402054.htm.23.Health Canada. Summary safety review - testosterone replacement products - cardiovascular risk [Internet]. Ottawa (ON): Health Canada; 2015 [cited 2015
testosterone 44605 Canada; 2015 [cited 2015 Jul 26]. Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/ testosterone -eng.php.24.Layton JB, et al. Comparative safety of testosterone dosage forms. JAMA Intern Med 2015;175:1187-96.25.Nguyen
testosterone 44669 http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/testosterone-eng.php.24.Layton JB, et al. Comparative safety of testosterone dosage forms. JAMA Intern Med 2015;175:1187-96.25.Nguyen CP, et al. Testosterone and "Age-Related Hypogonadism"--FDA
testosterone 45572 available for review.There appears to be no change in mortality risk overall for men utilizing long-term testosterone therapy.Tan RS, et al. Int J Endocrinol 2015;2015:970750.Electronic medical records were queried between
testosterone 46005 factors.Baillargeon J, et al. Ann Pharmacother 2014;48:1138-1144.6,355 Patients treated with at least 1 injection of testosterone matched to 19,065 testosterone nonusersOlder men who were treated with intramuscular testosterone did
testosterone 46036 2014;48:1138-1144.6,355 Patients treated with at least 1 injection of testosterone matched to 19,065 testosterone nonusersOlder men who were treated with intramuscular testosterone did not appear to have an increased
testosterone 46103 of testosterone matched to 19,065 testosterone nonusersOlder men who were treated with intramuscular testosterone did not appear to have an increased risk of MI.Etminan M, et al. Pharmacotherapy 2015;35:72-8.934,283
testosterone 46468 al. Am J Cardiol 2016;117:794-9.A total of 4,736 men were studied. Subjects supplemented to normal testosterone had reduced 3-year MACE (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.56–0.98, p=0.04)
testosterone 46611 (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.56–0.98, p=0.04) compared to persistently low testosterone “We found no support for recent reports that there is an increased risk soon after initiation of TRT.
testosterone 46804 after initiation of TRT. A novel finding of this study is its ability to evaluate differing levels of testosterone achieved by treatment.”Wallis CJ, et al. Lancet Diabetes Endocrinol 2016;4:498-506.10,311 Men treated
testosterone 46926 by treatment.”Wallis CJ, et al. Lancet Diabetes Endocrinol 2016;4:498-506.10,311 Men treated with testosterone and 28,029 controls with a median followup of 5.3 years. Patients treated with testosterone had lower
testosterone 47018 treated with testosterone and 28,029 controls with a median followup of 5.3 years. Patients treated with testosterone had lower mortality than did controls (HR, 0.88; 95% CI, 0.84–0.93). Patients in the lowest tertile
testosterone 47136 lower mortality than did controls (HR, 0.88; 95% CI, 0.84–0.93). Patients in the lowest tertile of testosterone exposure had increased risk of mortality (HR, 1.11; 95% CI, 1.03–1.20) and cardiovascular events (HR,
testosterone 47349 (HR, 1.26; 95% CI, 1.09–1.46) compared with controls. By contrast, those in the highest tertile of testosterone exposure had decreased risk of mortality (HR, 0.67; 95% CI, 0.62–0.73) and cardiovascular events (HR,
testosterone 47568 0.84; 95% CI, 0.72–0.98), with a significant trend across tertiles (p<0.0001).Long-term exposure to testosterone replacement therapy was associated with reduced risks of mortality, cardiovascular events, and prostate
testosterone 47785 cancer.Snyder PJ, et al. N Engl J Med 2016;374:611-24.790 Men 65 years of age or older with a serum testosterone concentration of less than 275 ng per deciliter and symptoms of hypoandrogenism received either testosterone
testosterone 47894 testosterone concentration of less than 275 ng per deciliter and symptoms of hypoandrogenism received either testosterone gel or placebo gel for 1 year.Seven men in each study group had major cardiovascular events (myocardial
testosterone 48115 infarction, stroke, or death from cardiovascular causes) during the treatment period and two men in the testosterone group and nine men in the placebo group were adjudicated to have had major cardiovascular events during
testosterone 48282 adjudicated to have had major cardiovascular events during the subsequent year.CV, cardiovascular; TT, total testosterone ; MI, myocardial infarction; VTE, venous thromboembolism; ICD-9, international classification of diseases,
testosterone 48546 provider of information, services and technology for the healthcare industry around the world; TRT, testosterone replacement therapy; MACE, major adverse cardiovascular.Table 6Testosterone therapy does not increase
testosterone 48778 riskMeta-analyses studyNo. of studies included in the analysesT therapy resulted in:Isidori AM, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin
testosterone 49216 2007;82:29-39.30No Increase in CVD RiskFernández-Balsells MM, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-75.51No
testosterone 49403 Endocrinol Metab 2010;95:2560-75.51No Increase in CVD RiskCalof OM, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials.
testosterone 49825 randomized trials. BMC Med 2013;11:108.27Increase in CVD RiskCorona G, et al. Therapy of endocrine disease: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol 2016;174:R99-116.59No
testosterone 50382 and meta-analysis. Mol Neurobiol 2016;53:2679-84.7No Increase in CVD RiskNeto WK, et al. Effects of testosterone on lean mass gain in elderly men: systematic review with meta-analysis of controlled and randomized
testosterone 50607 (Dordr) 2015;37:9742.11No Increase in CVD RiskCorona G, et al. Cardiovascular risk associated with testosterone -boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 2014;13:1327-51.74No
testosterone 50780 Expert Opin Drug Saf 2014;13:1327-51.74No Increase in CVD RiskGuo C, et al. Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials. Exp
Select Disease Character Offset Disease Term Instance
diabetes mellitus 38171 androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. Int J Cardiol 2010;143:343-8.“In diabetic men with stable CAD,
hypogonadism 858 many in the medical community remain hesitant to utilize this therapeutic approach to treat men with hypogonadism . As the fears concerning prostate cancer have subsided, a new controversy regarding use of testosterone
hypogonadism 2023 witnessed a revolution in medical management of men with testosterone (T) deficiency (TD; also known as hypogonadism ) [[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]]. TD has been recognized for more than 7 decades
hypogonadism 4911 road block to advancing T therapy in men with TD. Finally, the FDA also suggested that age-related hypogonadism does not warrant treatment and only TD with recognized etiology merits treatment [[39]]. In this review,
hypogonadism 5354 T therapy and the future of this rapidly changing field in men's health.TESTOSTERONE DEFICIENCYTD ( hypogonadism ) was recognized, as early as 1940s [[16][17][18]] as significant medical condition, which adversely
hypogonadism 26195 al. [[3]] and the resolutions of the consensus panel on T [[2]] debunked the notion that age-related hypogonadism is not a clinical condition and should remain untreated. As reported in the study [[3]], T therapy in
hypogonadism 26357 untreated. As reported in the study [[3]], T therapy in older men has several benefits and age-related hypogonadism is a clinical condition worthy of treatment. We hope that the findings of this large and well executed
hypogonadism 35641 replacement may improve survival in hypogonadal men with type 2 diabetes.”7. Pye SR, et al. Late-onset hypogonadism and mortality in aging men. J Clin Endocrinol Metab 2014;99:1357-66.“Severe LOH is associated with
hypogonadism 40587 for coronary angiography.”DHT, dihydrotestosterone; IHD, ischemic heart disease; LOH, late onset hypogonadism ; CVD, cardiovascular disease; HD, hemodialysis; ESRD, end-stage renal disease; MACE, major adverse cardiovascular
hypogonadism 43321 Hypogonadism"--FDA Concerns. N Engl J Med 2015;373:689-91.17.Murphy EN, et al. Doubts about treating hypogonadism due to long-term opioid use with testosterone therapy: a teachable moment. JAMA Intern Med 2014;174:1892-3.18.Wierman
hypogonadism 45750 2015;2015:970750.Electronic medical records were queried between the years 2009 and 2014 to identify patients diagnosed with hypogonadism , MI, and stroke, as indicated by ICD-9 codes.Testosterone is generally safe for younger men who do not
hypogonadism 50825 Increase in CVD RiskGuo C, et al. Efficacy and safety of testosterone replacement therapy in men with hypogonadism : A meta-analysis study of placebo-controlled trials. Exp Ther Med 2016;11:853-63.16No Increase of death
metabolic syndrome 5534 medical condition, which adversely impacts men's health. TD is associated with increased incidence of metabolic syndrome , obesity, sexual dysfunction, impaired fertility, reduced motivation, increased fatigue, depressed mood,
metabolic syndrome 9458 role in cardiovascular function [[5][6][7]]. A host of cardiovascular risk factors such as obesity, metabolic syndrome , dyslipidemia, hypertension, insulin resistance and diabetes are increased with TD [[5][6][7]]. T therapy
metabolic syndrome 9718 body weight, waist circumference, and BMI (Tables 1 and 2) [[4][8][41]]. T therapy also ameliorates metabolic syndrome components [[4][49]], improves lipid profiles (Fig. 3), reduces blood glucose and hemoglobin A1c (Fig.
metabolic syndrome 11938 therapy in ameliorating lower urinary tract symptoms (LUTS). T protects lower urinary tract (LUT) from metabolic syndrome -induced alterations and T treatment in animals with metabolic syndrome (MetS) counteracts the MetS-induced
metabolic syndrome 12009 lower urinary tract (LUT) from metabolic syndrome-induced alterations and T treatment in animals with metabolic syndrome (MetS) counteracts the MetS-induced LUT alterations and attenuates the progression of LUTS [[62]]. Kathrins
metabolic syndrome 25146 this review, show that T therapy has many health related benefits. These include amelioration of the metabolic syndrome components, reduction in fat mass and increased LBM, reduced body weight and waist circumference, increased
obesity 5554 which adversely impacts men's health. TD is associated with increased incidence of metabolic syndrome, obesity , sexual dysfunction, impaired fertility, reduced motivation, increased fatigue, depressed mood, loss
obesity 9449 important role in cardiovascular function [[5][6][7]]. A host of cardiovascular risk factors such as obesity , metabolic syndrome, dyslipidemia, hypertension, insulin resistance and diabetes are increased with
obesity 17507 somatic and sexual subscale scores [[87]]. In a cohort of 223 patients, after adjustments for age and obesity men with normal T levels had significantly better physical and mental health as well as treatment satisfaction
obesity 27084 "Comeback Kid".Fig. 1Testosterone therapy in men with testosterone deficiency and differing grade of obesity produces significant and sustained weight loss. Hypogonadal men (n=362) with obesity grade I (Gr. I:
obesity 27169 differing grade of obesity produces significant and sustained weight loss. Hypogonadal men (n=362) with obesity grade I (Gr. I: n=185; mean age, 58.39±8.04 years), grade II (Gr. II: n=131; mean age, 60.62±5.56
obesity 27597 2010;58:1134-43 [[74]].Fig. 2Testosterone therapy in men with testosterone deficiency and differing grade of obesity produces marked and sustained reductions in waist circumference. Waist circumference (WC) (cm) in 362
obesity 27728 sustained reductions in waist circumference. Waist circumference (WC) (cm) in 362 hypogonadal men with obesity grade I (Gr. I: n=185; mean age, 58.39±8.04 years), grade II (Gr. II: n=131; mean age, 60.62±5.56

You must be authorized to submit a review.